anticonvulsant as they were imminently dying. Where prognosis was estimated, 80% of patients commencing a midazolam CSCI were felt likely to survive less than a week Seizures were controlled in 69% of patients with initial doses prescribed. 'As required' anticonvulsant medication was prescribed for 23 patients (88%); all were prescribed subcutaneous midazolam (2.5 mg-10 mg). Phenobarbital (8 patients), buccal midazolam (one patient) and rectal diazepam (one patient) were also prescribed. The majority of patients (92%) died and almost half (46%) died within a week of parenteral anticonvulsant prescription. Conclusion Levetiracetam via CSCI was the most commonly used parenteral anticonvulsant. Midazolam via CSCI tended to be used for patients with a poorer prognosis (under one week). Regional guidelines need to be reviewed to reflect clinical practice. Given the widespread use of levetiracetam, further research is warranted to guide use in the palliative care setting. Background Syringe drivers are routinely used in palliative medicine for the subcutaneous infusion of drugs. Local site reactions can lead to patient discomfort and the potential for sub-optimal symptom control. A site reaction is defined as 'an adverse incident occurring at the point of drug delivery'. Anecdotally, we observed frequent site reactions in our clinical practice without formal record of prevalence within our inpatient unit. We decided to perform an audit to determine whether our practice is in keeping with local/national guidance and whether outcomes were within acceptable limits. Background Delirium is a syndrome of decreased cognitive function, consciousness and attention. It has an acute onset and fluctuating course. The prevalence of delirium amongst palliative care in-patients is about 30%. There is no similar data for out-patients. A focus group was conducted at a Scottish hospice to explore the experiences of clinical nurse specialists (CNSs) in managing delirium in the community. This formed part of a wider quality improvement project on hospice patients with delirium. Method Two facilitators explored the experiences of CNSs in the management of delirium. Discussions were recorded and transcribed to allow analysis of themes. Results The focus group involved eight CNSs and generated 21 pages of text. Data was reviewed by two members of the project team. Themes emerged including importance of skilled assessment, impact on families, challenges in the management of delirium at home and the impact of delirium on choices available at the end of life.
Background Syringe drivers are routinely used in palliative medicine for the subcutaneous infusion of drugs. Local site reactions can lead to patient discomfort and the potential for sub-optimal symptom control. A site reaction is defined as 'an adverse incident occurring at the point of drug delivery'. Anecdotally, we observed frequent site reactions in our clinical practice without formal record of prevalence within our inpatient unit. We decided to perform an audit to determine whether our practice is in keeping with local/national guidance and whether outcomes were within acceptable limits. Background Delirium is a syndrome of decreased cognitive function, consciousness and attention. It has an acute onset and fluctuating course. The prevalence of delirium amongst palliative care in-patients is about 30%. There is no similar data for out-patients. A focus group was conducted at a Scottish hospice to explore the experiences of clinical nurse specialists (CNSs) in managing delirium in the community. This formed part of a wider quality improvement project on hospice patients with delirium. Method Two facilitators explored the experiences of CNSs in the management of delirium. Discussions were recorded and transcribed to allow analysis of themes. Results The focus group involved eight CNSs and generated 21 pages of text. Data was reviewed by two members of the project team. Themes emerged including importance of skilled assessment, impact on families, challenges in the management of delirium at home and the impact of delirium on choices available at the end of life.
The CNSs reflected on the impact of delirium on patients' families, who experienced guilt, fear and a sense of early bereavement. They also recognised particular challenges associated with managing patients with delirium in the community. They felt pressure to avoid admission to hospital but also felt there was a lack of the support services required to offer a non-pharmacological approach to management at home. Drugs were resorted to earlier than would be necessary in a different care setting to manage symptoms and risk. The CNSs also spoke of 'walking away' but being left with feelings of responsibility for the situation. Delirium was also felt to negatively impact on choices at the end of life e.g. place of death. Conclusion Management of delirium in the community represents unique challenges compared with an in-patient setting. There is a need for educational resources targeting professionals working in the community. 
